ImClone News
Most Popular ImClone Story
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the... Read more...
Latest Headlines
- July 23, 2009
- January 14, 2009
- October 15, 2008
- October 6, 2008
- October 3, 2008
- October 2, 2008
- October 1, 2008
- September 29, 2008
- September 24, 2008
- September 23, 2008
- September 16, 2008
- September 12, 2008
- September 11, 2008
- September 10, 2008
- August 28, 2008
- August 21, 2008
- August 15, 2008
- August 11, 2008
- August 4, 2008
- July 31, 2008
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
